CDK7 Degrader
-
BSJ-5-63
0 ImagesBSJ-5-63 is a potent CDK12, CDK7, CDK9 PROTAC degrader. BSJ-5-63 BSJ-5-63 decreases the protein expression of CDK12, CDK7, CDK9, RNAPII, Cyclin K. BSJ-5-63 decreases the mRNA expression of BRCA1, BRCA2. BSJ-5-63 shows anticancer activity and has the potential for the research of prostate cancer.
-
CDK7 ligand 2
0 ImagesCDK7 ligand 2 (Compound A6) is a CDK7 ligand. CDK7 ligand 2 can be used in the synthesis of PROTACs.
-
TMX-2138
0 ImagesTMX-2138 is a CDK PROTAC degrader, with IC50 values against different targets as follows: CDK1 (IC50 = 8.7 nM), CDK2 (IC50 = 10.9 nM), CDK5 (IC50 = 7.0 nM), CDK4 (IC50 = 901.0 nM), CDK6 (IC50 = 465.0 nM), CDK7 (IC50 = 286.0 nM), and CDK9 (IC50 = 25.7 nM). TMX-2138 promotes the ubiquitination of CDK and induces its degradation via the proteasomal pathway. TMX-2138 can be used in ovarian cancer research.
-
CDK7 ligand 3
0 ImagesCat. No.: HY-183071CAS No.: 3040999-61-6CDK7 ligand 3 is a target protein ligand for CXJ2080 (HY-183070), which be used for the research of acute leukemia.
-
CXJ2080
0 ImagesCat. No.: HY-183070CXJ2080 is a selective PROTAC-based CDK7 degrader with a DC50 of 0.88 nM. CXJ2080 recruits VHL E3 ligase to induce ubiquitin-proteasome-dependent CDK7 degradation, disrupts the CDK7-cyclin H-MAT1 complex, suppresses CDK7-dependent phosphorylation of RNA polymerase II CTD Ser5, CDK1 Thr161, and CDK2 Thr160. CXJ2080 activates the p53-p21 axis, suppresses MYC-driven signaling, induces leukemia cell cycle arrest, apoptosis, and differentiation, reduces CD117 expression, spares platelets and normal PBMCs, maintains sustained CDK7 degradation post-washout. CXJ2080 can be used for the research of acute leukemia.
